Patents by Inventor Brian Campion

Brian Campion has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
    Publication number: 20230348589
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Application
    Filed: January 27, 2023
    Publication date: November 2, 2023
    Inventors: Anke Kretz-Rommel, Lei Shi, Roger Ferrini, Teddy Yang, Fei Xu, Brian Campion
  • Treatment of disease responsive to modulation of cannabanoid 1(CB1) receptor signaling
    Patent number: 11566069
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: January 31, 2023
    Assignee: Bird Rock Bio, Inc.
    Inventors: Anke Kretz-Rommel, Lei Shi, Roger Ferrini, Teddy Yang, Fei Xu, Brian Campion
  • Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
    Publication number: 20190315856
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Application
    Filed: January 25, 2019
    Publication date: October 17, 2019
    Inventors: Anke Kretz-Rommel, Lei Shi, Roger Ferrini, Teddy Yang, Fei Xu, Brian Campion
  • Antibodies that bind human cannabinoid 1 (CB1) receptor
    Patent number: 10308712
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: June 4, 2019
    Assignee: BIRD ROCK BIO, INC.
    Inventors: Anke Kretz-Rommel, Lei Shi, Roger Ferrini, Teddy Yang, Fei Xu, Brian Campion
  • Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
    Publication number: 20170210797
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Application
    Filed: March 27, 2015
    Publication date: July 27, 2017
    Inventors: Anke Kretz-Rommel, Lei Shi, Roger Ferrini, Teddy Yang, Fei Xu, Brian Campion
  • Topical antiandrogen for hair loss and other hyperandrogenic conditions
    Patent number: 6828458
    Abstract: Compound (2-hydroxy-2-methyl-N-(4-X-3-(trifluoromethyl)phenyl)-3-(2,2,2-perfluoroacylamino)propionamide) applied topically, specifically inhibits and/or eliminates cutaneous androgen receptors and thus finds cosmetic use in skin afflictions associated with excess androgens such as hair effluvium, hirsutism, acne and androgenic alopecia.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: December 7, 2004
    Assignee: Biophysica, Inc.
    Inventors: Milos Sovak, Allen L. Seligson, Brian Campion, Jason W. Brown
  • A TOPICAL ANTIANDROGEN FOR HAIR LOSS AND OTHER HYPERANDROGENIC CONDITIONS
    Publication number: 20040014732
    Abstract: Compound (2-hydroxy-2-methyl-N-(4-X-3-(trifluoromethyl)phenyl)-3-(2,2,2-perfluoroacylamino)propionamide) applied topically, specifically inhibits and/or eliminates cutaneous androgen receptors and thus finds cosmetic use in skin afflictions associated with excess androgens such as hair effluvium, hirsutism, acne and androgenic alopecia.
    Type: Application
    Filed: May 25, 2000
    Publication date: January 22, 2004
    Applicant: Biophysica, Inc.
    Inventors: Milos Sovak, Allen L Seligson, Brian Campion, Jason W Brown
  • Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
    Patent number: 6472415
    Abstract: Substituted phenylalanines are provided comprising an hydantoin, urea or 2-hydroxyl, 2-methylpropionyl group, dimers thereof and alkyl, polyfluoroamido and haloarylamino derivatives thereof, as well as radiolabeled derivatives thereof. The compounds bind specifically to the androgen receptor and find use in indications associated with the androgen receptor, such as cell hyperplasia dependent on androgens, hirsutism, acne and androgenetic alopecia.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: October 29, 2002
    Assignee: Biophysica, Inc.
    Inventors: Milos Sovak, Allen L. Seligson, James Gordon Douglas, III, Brian Campion, Jason W. Brown
  • Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
    Patent number: 6184249
    Abstract: Substituted phenylalanines are provided comprising an hydantoin, urea or 2-hydroxyl, 2-methylpropionyl group, dimers thereof and alkyl, polyfluoroamido and haloarylamino derivatives thereof, as well as radiolabeled derivatives thereof. The compounds bind specifically to the androgen receptor and find use in the therapy of indications associated with the androgen receptor, such as, hirsutism, acne and androgenetic alopecia, and in the therapy and diagnosis of cell hyperplasia dependent on androgens.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: February 6, 2001
    Assignee: Biophysica, Inc.
    Inventors: Milos Sovak, Allen L. Seligson, James Gordon Douglass, III, Brian Campion, Jason W. Brown
  • Biodegradable blood-pool contrast agents
    Patent number: 6010681
    Abstract: The invention provides a blood pool contrast agent having an overall molecular weight of at least 10KD comprising a macrostructure which has bound thereto a plurality of opsonization inhibiting moieties and carries chelated ionic paramagnetic or heavy metal moieties, the chelant groups for said chelated moieties being macrocyclic where said macrostructure is liposomal.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: January 4, 2000
    Assignee: Nycomed Salutar, Inc.
    Inventors: Larry Margerum, Brian Campion, Jere Douglas Fellmann, Martha Garrity, John Varadarajan
  • Dendrimeric compounds
    Patent number: 5834020
    Abstract: The invention provides a dendrimeric compound comprising a dendrimeric bioactive moiety with linked thereto a plurality of diagnostically or therapeutically active moieties characterized in that the molecular skeleton of said compound contains at least one biodegradable cleavage site such that on cleavage thereof said active moieties are released in renally excretable form.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: November 10, 1998
    Assignee: Nycomed Salutar, Inc.
    Inventors: Larry Margerum, Brian Campion, Jere Douglas Fellmann, Martha Garrity
  • Androgenic directed compositions
    Patent number: 5656651
    Abstract: Substituted phenylthiohydantoins are provided for use in detecting the presence of tumor cells having androgenic receptors and providing for cytostatic and cytotoxic activity toward such cells. The subject compounds provide for vehicles for specific targeting to the androgenic receptor containing cells of cytostatic and/or cytotoxic agents, heavy or light radioactive or radioopaque atoms, and the like for detection and treatment of cancer cells involving androgenic receptors or blocking androgenic receptors.
    Type: Grant
    Filed: June 16, 1995
    Date of Patent: August 12, 1997
    Assignee: Biophysica Inc.
    Inventors: Milos Sovak, Jerome C. Bressi, James Gordon Douglass, III, Brian Campion, Wolfgang Wrasidlo